CD274 and pneumonitis: By identifying patientswith high PD-L1 expression and an active antitumor immune response,PET imaging can guide the selection of individuals who are most likelyto respond to PD-L1 checkpoint inhibitor therapy.2 This personalized approach holds the potential to minimizetreatment-related adverse events (fatigue, pruritus, diarrhea, endocrinedysfunction, pneumonitis) and optimize therapeutic outcomes.